China’s 2026 Anti-Corruption Plan: What 14 Ministries Changed for IOL Market Access
On 8 June 2026, 14 ministries tightened four parts of the medical-device commercial chain at once. For IOL, the most exposed practice is the one that has no equivalent in pharmaceuticals.
Four lines, tightened together
On 8 June 2026, the National Health Commission announced that 14 ministries had jointly issued the 2026 Work Plan to Correct Misconduct in Pharmaceutical Purchasing and Healthcare Services, which included 11 priority tasks. High-value consumables and medical equipment are named as procurement-supervision priorities. Four of the tasks bite on an intraocular lens business at the same time.
The first is tax enforcement on invoicing: the plan targets falsified invoicing, fraudulent VAT invoices and concealed income in the device sector, and, notably, commits to tracing the institutions that accept false invoices. The second is the boundary of academic engagement: kickbacks delivered under a research or academic label are named as a priority target. The third is medical-data security, with a ban on unauthorised use and data profiteering. The fourth, appearing in a misconduct work plan for the first time, is research into direct settlement between medical insurance and suppliers.
The gap that matters: drugs are regulated, devices are not yet
The Measures for the Administration of Pharmaceutical Sales Representatives (2026年第42号) were issued on 28 April 2026 and take effect on 1 August 2026, setting nine prohibited behaviours for drug representatives. The same notice states that the rules governing device-company personnel who carry out product information and academic promotion activities in medical institutions will be formulated separately. No date is attached.
That is the policy-execution gap worth planning around. The engagement practices the drug rule now prohibits remain, for devices, formally unregulated, yet they are already reachable through the anti-corruption plan’s clause on benefits delivered under a research label. Device promotion is exposed to enforcement before it is governed by a dedicated rule. The high-end IOL field, where adoption is taught through department meetings, surgical demonstration and manufacturer support in the operating theatre, sits squarely inside that exposure.
Settlement is named, not built
Research into direct medical-insurance-to-supplier settlement is named in the plan, but no implementing rule, timetable or responsible authority is published. For domestic IOL suppliers, direct settlement would materially shorten receivables, but until a binding scheme appears, it is a probable, undated improvement, not a current entitlement.
Where enforcement bites first
Where enforcement lands first is an empirical question, and the published record answers it. Ophthalmology is one of seven priority domains named for 2026 on-site inspections, alongside orthopaedics, oncology, diagnostics, dentistry, general surgery and neurology. The penalty record is concentrated in private ophthalmology chains: Xiangshan Aier was fined RMB 131,500 for billing a covered item in place of an excluded one; Nanchang Aier was ordered to return RMB 515,000 and fined RMB 772,400 in January 2026, a repeat after a March 2025 penalty; Xuchang Aier had RMB 74,900 of illicit gains confiscated and was fined RMB 120,000 for referral-fee inducement. In 2024 a National Health Commission reply found several affiliated hospitals suspected of issuing false diagnostic certificates, with commercial bribery implicated at individual sites.
Public tertiary eye centres are inspected too, but eye-specific penalty cases are rare, and their procurement and academic-activity records are more mature under diagnosis-related-group discipline. The reading is sequence, not exemption: private chains first, larger public providers reached later. The enforcement baseline is not small. In the first half of 2025 alone, RMB 16.13bn was recovered across 335,000 institutions.
What it means for an IOL business
The plan re-prices three practices much of the field still relies on: invoice-based channel financing, physician engagement carried under an academic label, and the data-sharing arrangements behind real-world evidence. The single most exposed is manufacturer clinical support inside the operating theatre, a device-specific practice with no pharmaceutical equivalent, and the hardest to document as a clinical necessity rather than a volume-linked activity.
For the largest private operator, the backdrop is growth pressure: Aier Ophthalmology reported 2025 revenue of RMB 22.35bn, up 6.53 per cent, and net profit attributable to the parent of RMB 3.24bn, down 8.88 per cent. The combination of margin pressure and tightening enforcement is the context in which 2026 commercial planning has to be done.
The 30-day action framework, the scenario magnitudes and the layer-by-layer exposure of physician engagement are set out in the Commercial Execution Brief for this signal, available to market access and investment teams on request.
Key Implications
Treat the open device-promotion window as a planning runway, not a reprieve. Prioritise the two practices most likely to trigger an audit line: in-theatre support and department-meeting financing. Expect a private-first, public-later enforcement sequence, and read each new ophthalmology inspection case for the spread pattern. Model direct settlement as a probable but undated improvement, not a present fact.
Request the brief
The Commercial Execution Brief for this signal contains the policy document references, the three-scenario analysis and a 30-day action framework for market access, medical-affairs and investment teams. It is supplied on a restricted basis.
This article is provided for information only. It does not constitute legal, regulatory, investment or medical advice. Policy positions and enforcement practice change; verify any regulatory development independently against the primary source before acting. OphthalLogix Intelligence accepts no liability for any reliance placed on this content. intelligence@ophthallogix.com · www.ophthallogix.com